- Details
- John Babich discusses the potential of radiopharmaceuticals in cancer treatment. He emphasizes the importance of targeting and retention in tumor tissues, explaining the concept of therapeutic index and the company's "radioligand first, isotope second" approach. Dr. Babich highlights their work on FAP (fibroblast activation protein) and their Trillium technology, which aims to optimize drug delive...
|
- Details
- Francesco Soria discusses a study validating the IBCG scoring system for intermediate-risk bladder cancer. He explains the heterogeneity of this risk group and the need for better stratification. Soria describes the IBCG model, which uses five risk factors to divide patients into three subgroups. The study validates this model using a large European cohort, showing significant differences in recur...
|
- Details
- Ashish Kamat interviews Felix Guerrero-Ramos about a European Urology Oncology review on novel treatments for non-muscle-invasive bladder cancer (NMIBC). Dr. Guerrero-Ramos presents an overview of emerging therapies across different risk categories of NMIBC, focusing on intravesical and systemic approaches. He highlights FDA-approved treatments for BCG-unresponsive disease and ongoing trials for B...
|
- Details
- Sam Chang interviews Jason Brown about research on disparities in bladder cancer mortality between urban and rural settings from 2000 to 2020. Dr. Brown presents findings showing a significant decline in bladder cancer mortality in urban areas, particularly large metropolitan centers, while rates remain unchanged in rural areas. The study uses CDC data and Joinpoint Regression analysis to identify...
|
- Details
- In this discussion, Sam Chang interviews Saum Ghodoussipour about the role of circulating tumor DNA (ctDNA) as a biomarker in urothelial carcinoma. Dr. Ghodoussipour presents an overview of ctDNA's potential applications in various stages of bladder cancer, from non-muscle invasive to advanced disease. He highlights its utility in early detection, risk stratification, and monitoring treatment resp...
|
- Details
- Sam Chang host Mario de Angelis to discuss a study on trimodal therapy (TMT) for urothelial and non-urothelial invasive bladder cancer. Dr. De Angelis presents findings from a SEER database analysis of over 5,000 patients treated with TMT. The study reveals that TMT use has increased for organ-confined urothelial carcinoma but decreased for non-urothelial cases. For organ-confined disease, patient...
|
- Details
- Ashish Kamat interviews Shilpa Gupta about the best of ASCO 2024 in advanced bladder cancer. Dr. Gupta discusses three abstracts: the CheckMate-901 trial's analysis of complete responders to Nivolumab plus gemcitabine-cisplatin in lymph node-only metastatic urothelial cancer; patient-reported outcomes from the EV-302 trial comparing enfortumab vedotin plus pembrolizumab to platinum chemotherapy; a...
|
- Details
- Ashish Kamat interviews Omar Alhalabi about research on small cell neuroendocrine carcinoma of the urinary tract. Dr. Alhalabi discusses the study's findings on prognostic factors for relapse in surgically resected cases. The research reveals that neoadjuvant chemotherapy benefits patients, while the persistence of small cell carcinoma at surgery is associated with a high risk of relapse. The stud...
|
- Details
- Sam Chang interviews Elias Chandran about a systematic review and meta-analysis on mismatch repair deficiency (dMMR) and microsatellite instability (MSI-H) in urothelial carcinoma. Dr. Chandran presents findings showing higher prevalence of dMMR and MSI-H in upper tract urothelial carcinoma compared to bladder cancer, with greater frequency in localized disease than metastatic disease. The study s...
|
- Details
- Sam Chang and Bernard Bochner discuss a novel antibody treatment targeting the CD40 receptor for non-muscle invasive bladder cancer resistant to BCG therapy. Dr. Bochner presents findings from a phase one study showing promising results with minimal toxicity. The treatment activates dendritic cells, leading to CD8+ T cell recruitment and tumor elimination. Preliminary data indicates a 50% complete...
|
